T-CURX
T-CURX is a biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing a proprietary platform, T-CURX aims to advance the field of T cell therapies to address the challenges faced in treating various cancers. The company's innovative approach involves the creation of a new generation of T cells designed to improve patient outcomes. As a spin-out from the University Clinics Würzburg, Germany, T-CURX leverages the expertise of its co-founders, including Prof. Michael Hudecek, to pioneer in the area of CAR-T cell-based medicines. With a commitment to transforming cancer treatment, T-CURX is at the forefront of developing targeted therapies that offer hope for a more effective and personalized approach to cancer care.
T-CURX
Social Links:
Industry:
Biotechnology Chemical Oncology
Founded:
2017-01-01
Address:
Würzburg, Bayern, Germany
Country:
Germany
Website Url:
http://www.t-curx.com
Total Employee:
1+
Status:
Active
Contact:
+49 0 931 250 99 712
Email Addresses:
[email protected]
Similar Organizations
Ceradis
Ceradis develops environmental friendly solutions for plant nutrition, crop protection and formulation technology.
Cumulus Oncology
Cumulus Oncology develops anti-cancer therapies for clinical settings in areas of high unmet need.
Nano Clinical
Nano Clinical develops a novel microscopy technology to help design and develop better cancer treatments for patients.
PhotoBiotics
PhotoBiotics is develops targeted therapeutics for MRI imaging and cancer treatment.
Current Employees Featured
Founder
Official Site Inspections
http://www.t-curx.com Semrush global rank: 9.59 M Semrush visits lastest month: 413
- Host name: inn.host.ch
- IP address: 80.74.150.210
- Location: Neunkirch Switzerland
- Latitude: 47.6901
- Longitude: 8.4998
- Timezone: Europe/Zurich
- Postal: 8213
More informations about "T-CURX"
T-Curx - Company
The commercial translation of T-CURX’ transformative CAR-T technologies and CAR-T cell products is led by T-CURX’ experienced leadership team headed by Ulf Grawunder as CEO. T …See details»
Company Fact Sheet - T-CURX
T-CURX GmbH Innovation and Founder Centre Friedrich-Bergius-Ring 15 97076 Würzburg Deutschland P: +49-(0)-931-250-99-712 E: [email protected] W: www.t-curx.com Pioneering …See details»
T-CURX - Crunchbase Company Profile & Funding
T-CURX is a biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing a proprietary platform, T-CURX aims to advance the field of T cell …See details»
T-Curx Company Profile 2024: Valuation, Funding & Investors
T-Curx General Information Description. Developer of a new generation of T cells intended for personalized cancer immunotherapy. The company's cell technology platform includes virus …See details»
T-CURX - Innovations- und Gründerzentrum Biotechnologie IZB
T-CURX is a biopharmaceutical start-up company based in Würzburg and Munich, focusing on the development and commercialization of next-generation CAR-T cell therapies for cancer …See details»
T-CURX GmbH - LinkedIn
T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. …See details»
T-CURX - VentureRadar
T-CURX develops a new generation of T cells for personalized cancer immunotherapy, built on a proprietary platform that overcome challenges in safety & efficacy, manufacture & scalability …See details»
T-Curx GmbH, Germany - imSAVAR
Nov 16, 2024 T-CURX is a SME and Biotech spin-out from the partner UKW with expertise in pre-clinical, clinical and commercial development of ATMPs. T-CURX focuses on optimized …See details»
T-Curx - Personalized Cancer Immunotherapy
T-CURX develops a new generation of T cells for personalized cancer immunotherapy, built on a proprietary platform that overcome challenges in safety & efficacy, manufacture & scalability…See details»
Ulf Grawunder (T-Curx GmbH) - Life-Sciences-Europe.com
The proprietary CAR-T technologies of T-CURX were developed in the laboratory of co-founder Prof. Michael Hudecek at the University of Würzburg and are exclusively licensed to T-CURX. …See details»
Management - T-Curx
Innovations- und Gründerzentrum Würzburg Friedrich-Bergius-Ring 15 D-97076 Würzburg Deutschland/Germany. P: +49-(0)-931-250-99-712 W: www.t-curx.comSee details»
T-Curx
Christoph is co-founder of T-CURX and member of T-CURX’ Scientific Advisory Board. He is an internationally renowned expert in the development of antibody-based cancer therapies and …See details»
CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells ...
Apr 13, 2021 The central objective of the CARAMBA project is to conduct a first-in-human clinical trial with SLAMF7-specific CAR-T cells that have been prepared by virus-free SB gene …See details»
Target-4 chimeric antigen receptor T-cell therapy - T-CURX
A chimeric antigen receptor T-cell therapy acting at an undisclosed target-4 is being developed by T-CURX (a spin-off of University of Wuerzburg) for the Target-4 chimeric antigen receptor T …See details»
Technologies - T-Curx
Technologies. Our aim is to build a leading European CAR-T cell company.. For this ambition, T-CURX is leveraging proprietary and cutting-edge technologies and CAR-T product …See details»
Acute myeloid leukemia chimeric antigen receptor T-cell therapy
A chimeric antigen receptor T-cell therapy acting on an undisclosed target is being developed by T-CURX (a spin-off of University of Wuerzburg) for the Acute myeloid leukemia chimeric …See details»
T-CURX - News & Press Releases
T-CURX obtains exclusive license from the University of Würzburg, Germany, for a portfolio of 8 patent families, covering novel CAR-T cell technologies and products Read more. June 22, …See details»
Anti SLAMF7 chimeric antigen receptor T cell therapy - T-Curx
09 Sep 2020 T-CURX in-licenses CAR-T cell technology and patents from University of Wurzburg ; 22 Jun 2020 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) ... If …See details»
T-CURX - News & Press Releases
Successful completion of non-clinical tissue cross reactivity study for the binder of T-CURX CAR-T cell pipeline product for AML patients Read more. T-CURX GmbH. Innovations- und …See details»